Company: BIAF
Filing Date: 2025-10-27
Form Type: PRER14A
Source: 0001493152-25-019752
Chunk: 38

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-10-27
Form: PRER14A
Chunk 38
---
      
 that closed on August 14, 2025, that may be equal to or exceed 20% of our Common Stock outstanding before such offering (the “Warrant   
 Anti-Dilution Proposal”).                                                                                                               |

<div align='center'>FOR ☐ AGAINST ☐ ABSTAIN ☐</div>

| 3. | Proposal to consider and                                                                                                                 
 approve, pursuant to Nasdaq listing rules, the issuance of up to an aggregate of 131,884 shares of our Common Stock upon the triggering  
 of certain anti-dilution provisions of our Series B Convertible Preferred Stock issued in connection with our private placement offering 
 that closed on August 14, 2025, that may be equal to or exceed 20% of our Common Stock outstanding before such offering (the “Series     
 B Anti-Dilution Proposal”).                                                                                                              |

<div align='center'>FOR☐ AGAINST☐ ABSTAIN☐</div>

| 4. | Proposal                                                                                                                 
 to approve an amendment to the 2024 Equity Incentive Plan (the “2024 Plan”) to increase the number of shares             
 of Common Stock reserved for issuance thereunder to 750,000 shares from 66,666 shares (the “Plan Amendment Proposal  ”). |

<div align='center'>FOR☐ AGAINST☐ ABSTAIN☐</div>

| 5. | Proposal                                                                                                                     
 for authorization to issue securities in one or more non-public offerings in accordance with Nasdaq Marketplace Rule 5635(d) 
 (the “Offering Proposal”).                                                                                                   |

<div align='center'>FOR☐ AGAINST☐ ABSTAIN☐</div>

| 6. | Proposal                                                                                                                         
 to approve any change of control under Nasdaq Marketplace Rule 5635 that may result from the potential issuance of securities in 
 the non-public offerings (the “Change of Control Proposal”).                                                                     |

<div align='center'>FOR☐ AGAINST☐ ABSTAIN☐</div>

| 7. | Proposal                                                                                                                                   
 to consider and approve an adjournment of the Special Meeting to a later date, if necessary or appropriate, to permit further solicitation 
 and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Warrant       
 Exercise, the Warrant Anti-Dilution Adjustment Proposal, the Series B Anti-Dilution Adjustment Proposal, the Plan Amendment                
 Proposal, the Offering Proposal and/or the